Orgenesis Inc. Debt/Equity

Debt/Equity of ORGS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Debt/Equity growth rates and interactive chart. The debt-to-equity (D/E) ratio is calculated by dividing a company's total interest-bearing liabilities by its shareholder equity. These numbers are available on the balance sheet of a company's financial statements. The ratio is used to evaluate a company's financial leverage. The debt/equity ratio can be compared to a company's historical average or to peers. A ratio above 1 indicates the company has more debt than equity and a ratio above 3 is considered high. Below 0.5 means the company has little debt and significant capacity to expand it.

Highlights and Quick Summary

  • Debt/Equity for the quarter ending June 29, 2021 was 0.25 (a 5.09% increase compared to previous quarter)
  • Year-over-year quarterly Debt/Equity increased by 79.55%
  • Annual Debt/Equity for 2020 was 0.22 (a -89.87% decrease from previous year)
  • Annual Debt/Equity for 2019 was 2.13 (a 1157.73% increase from previous year)
  • Annual Debt/Equity for 2018 was 0.17 (a 30.31% increase from previous year)
Visit for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Debt/Equity of Orgenesis Inc.

Most recent Debt/Equityof ORGS including historical data for past 10 years.

Interactive Chart of Debt/Equity of Orgenesis Inc.

Orgenesis Inc. Debt/Equity for the past 10 Years (both Annual and Quarterly)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 0.25 0.24
2020 0.25 0.14 0.13 0.13 0.22
2019 2.13 1.02 0.68 0.21 2.13
2018 0.15 0.1 0.11 0.23 0.17
2017 0.55 0.72 0.78 0.54
2016 0.79 0.93 0.31 0.0 0.79
2015 -1.6 -1.6
2014 -0.84 -0.84
2013 -0.15 -0.15
2012 -0.14 -0.15
2011 0.0

Business Profile of Orgenesis Inc.

Sector: Healthcare
Industry: Biotechnology
Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company's POCare Network brings together patients, doctors, industry partners, research institutes, and hospitals for the clinical development and production of therapies worldwide. Orgenesis Inc. has a collaboration agreement with Savicell Diagnostics Ltd. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.